Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Foundation Grant

University of Alberta

$1,642,998.00

Cachexia, the last illness: Translational research on mechanisms, diagnostic criteria and clinical management

EF 2017-18

Résumé
Patients with cancer often experience noticeable weight loss, which can start prior to diagnosis and which rapidly increases when the disease reaches an advanced stage. Over the course of the disease, affected people become thin sometimes to the point of becoming "skin and bones". This wasting, known as cachexia, is causes patients to become weak, frail and increasingly dependent on others for daily tasks and self care. Wasting also has important medical implications. Patients with wasting show very poor ability to tolerate cancer treatments and are sometimes forced to stop chemotherapy early due to severe side effects. There are no approved treatments for cancer-associated wasting. While all of the reasons for this are unclear, we may simply know too little about how body weight is controlled in people with cancer to be able to succeed. My vision is to discover new ways to alleviate cancer associated wasting. I developed a highly successful and internationally acclaimed research team in this area, which is unrivalled in its capacity to make key strides forward so that we can alleviate the suffering associated with this condition. 1. I will develop standardized criteria for diagnosis and early detection, so that every patient with risk of developing wasting can be identified as early as possible. 2. I will work to reveal the diverse factors which lead to wasting, so that we can provide a personalized and specific treatment approach to each patient. 3. I will also develop personalized chemotherapy dosing to limit toxicity in patients with wasting, allowing them to complete and benefit from their treatment plan. 4. I will continue to catalyze research partnerships to rapidly advance basic and clinical research and multiply the productivity of this unique Canadian-led effort.
Programme
Foundation Grant
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
369298
Name
Baracos Vickie E
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Clinical
Prcname2
Foundation Grant
Projecttitle
Cachexia, the last illness: Translational research on mechanisms, diagnostic criteria and clinical management
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$1,642,998
Cihrequipment2
$0
Programname2
Foundation Grant
Keyworddelim
Anorexia; Body Composition; Cancer Cachexia; Cancer Chemotherapy; Cancer-Associated Malnutrition; Chemotherapy Toxicity; Energy Balance; Skeletal Muscle Atrophy; Translational Research
Abstract
Patients with cancer often experience noticeable weight loss, which can start prior to diagnosis and which rapidly increases when the disease reaches an advanced stage. Over the course of the disease, affected people become thin sometimes to the point of becoming "skin and bones". This wasting, known as cachexia, is causes patients to become weak, frail and increasingly dependent on others for daily tasks and self care. Wasting also has important medical implications. Patients with wasting show very poor ability to tolerate cancer treatments and are sometimes forced to stop chemotherapy early due to severe side effects. There are no approved treatments for cancer-associated wasting. While all of the reasons for this are unclear, we may simply know too little about how body weight is controlled in people with cancer to be able to succeed. My vision is to discover new ways to alleviate cancer associated wasting. I developed a highly successful and internationally acclaimed research team in this area, which is unrivalled in its capacity to make key strides forward so that we can alleviate the suffering associated with this condition. 1. I will develop standardized criteria for diagnosis and early detection, so that every patient with risk of developing wasting can be identified as early as possible. 2. I will work to reveal the diverse factors which lead to wasting, so that we can provide a personalized and specific treatment approach to each patient. 3. I will also develop personalized chemotherapy dosing to limit toxicity in patients with wasting, allowing them to complete and benefit from their treatment plan. 4. I will continue to catalyze research partnerships to rapidly advance basic and clinical research and multiply the productivity of this unique Canadian-led effort.
Competitiondate
201709
Approvedterm2
7 yrs 0 mth
Pinamesdelim
Baracos, Vickie E
Approvedterm
7 ans 0 mois
Cihrcontribution2
~ $1,642,998~ $0~